In a study of over 500 people with carpal tunnel syndrome, researchers found that 57 percent returned to work three days after being treated with UltraGuideCTR, a modality which enables real-time ultrasound guidance for carpal tunnel release.
Carpal tunnel syndrome reportedly affects eight million people annually in the United States with an average of 28 days missed from work as a result of this condition, according to the United States Bureau of Labor Statistics. However, emerging research suggests that real-time ultrasound-guided carpal tunnel release (CTR-US) could return the majority of treated patients back to work in three days.
In a multicenter study, presented at the recent American Society for Surgery of the Hand (ASSH) 2023 Annual Meeting, researchers reviewed postoperative data for a total of 544 patients (mean age of 50) who had CTR-US with UltraGlideCTR (Sonex Health).
Fifty-two percent of the patients had symptoms of carpal tunnel syndrome for two years prior to treatment with UltraGlideCTR, according to the study. The researchers noted that 76 percent of the cohort were employed full-time with 49 percent having desk-based work and 23 percent performing heavy manual labor. The study authors said 68 percent of patients had UltraGlideCTR treatment for their dominant hand and 20 percent had simultaneous bilateral carpal tunnel release.
The researchers found an overall median return to work of three days after ultrasound-guided carpal tunnel release for the study cohort. Specifically, the study authors noted that 57 percent of treated patients returned to work after three days, 74.6 percent returned to work five days after treatment and 87.8 percent had returned to work 10 days after treatment.
“Approximately 3 out of 4 patients treated with CTR-US can (return to work) within one standard work week,” noted lead study author Paul D. Paterson, M.D., who is in private practice in Vero Beach, Fla., and colleagues.
The researchers also noted that the mean time to return to work was consistently between two to four days post-procedure for all patient subgroups. These median return to work time was three days for women, who are reportedly more likely to develop carpal tunnel syndrome than men, four days for heavy manual laborers and three days for patients who had bilateral carpal tunnel release procedures, according to the study.
Reference
1. Paterson PD, Aguila DJ, Kirsch MJ, Miller L. Rapid return to work after carpal tunnel release with ultrasound guidance. Poster SPP0685 presented at the American Society for Surgery of the Hand 2023 Annual Meeting, Toronto, Canada. October 5-7, 2023.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.